Deubiquitinases in cancer

Rongbin Wei; Xiaodong Liu; Weixin Yu; Tianshu Yang; Wenping Cai; Junjun Liu; Xiao Huang; Guo-tong Xu; Shouliang Zhao; Jianhua Yang; Shangfeng Liu

doi:10.18632/oncotarget.3671

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Deubiquitinases in cancer

Rongbin Wei _, Xiaodong Liu, Weixin Yu, Tianshu Yang, Wenping Cai, Junjun Liu, Xiao Huang, Guo-tong Xu, Shouliang Zhao, Jianhua Yang and Shangfeng Liu

PDF | HTML | How to cite

Oncotarget. 2015; 6:12872-12889. https://doi.org/10.18632/oncotarget.3671

Metrics: PDF 4725 views | HTML 6094 views | ?

Abstract

Rongbin Wei1,*, Xiaodong Liu2,*, Weixin Yu3,*, Tianshu Yang1, Wenping Cai1, Junjun Liu1, Xiao Huang1, Guo-tong Xu1, Shouliang Zhao3, Jianhua Yang1, Shangfeng Liu3

1Department of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P. R. China

2Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, P. R. China

3Department of Stomatology, Huashan Hospital, Fudan University, Shanghai 200040, P. R. China

*These authors have contributed equally to this work

Correspondence to:

Shangfeng Liu, e-mail: [email protected]

Jianhua Yang, e-mail: [email protected]

Shouliang Zhao, e-mail: [email protected]

Keywords: deubiquitinases, cancer, ubiquitylation, inhibitor

Received: January 16, 2015 Accepted: April 24, 2015 Published: May 07, 2015

ABSTRACT

Deubiquitinases are deubiquitinating enzymes (DUBs), which remove ubiquitin from proteins, thus regulating their proteasomal degradation, localization and activity. Here, we discuss DUBs as anti-cancer drug targets.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3671

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Deubiquitinases in cancer

Abstract